1. Home
  2. TNGX vs PBT Comparison

TNGX vs PBT Comparison

Compare TNGX & PBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNGX
  • PBT
  • Stock Information
  • Founded
  • TNGX 2014
  • PBT 1980
  • Country
  • TNGX United States
  • PBT United States
  • Employees
  • TNGX N/A
  • PBT N/A
  • Industry
  • TNGX Biotechnology: Pharmaceutical Preparations
  • PBT Oil & Gas Production
  • Sector
  • TNGX Health Care
  • PBT Energy
  • Exchange
  • TNGX Nasdaq
  • PBT Nasdaq
  • Market Cap
  • TNGX 723.2M
  • PBT 740.1M
  • IPO Year
  • TNGX N/A
  • PBT N/A
  • Fundamental
  • Price
  • TNGX $6.90
  • PBT $16.45
  • Analyst Decision
  • TNGX Strong Buy
  • PBT
  • Analyst Count
  • TNGX 6
  • PBT 0
  • Target Price
  • TNGX $10.00
  • PBT N/A
  • AVG Volume (30 Days)
  • TNGX 1.9M
  • PBT 168.6K
  • Earning Date
  • TNGX 08-05-2025
  • PBT 01-01-0001
  • Dividend Yield
  • TNGX N/A
  • PBT 3.25%
  • EPS Growth
  • TNGX N/A
  • PBT N/A
  • EPS
  • TNGX N/A
  • PBT 0.35
  • Revenue
  • TNGX $24,296,000.00
  • PBT $18,413,820.00
  • Revenue This Year
  • TNGX N/A
  • PBT N/A
  • Revenue Next Year
  • TNGX N/A
  • PBT N/A
  • P/E Ratio
  • TNGX N/A
  • PBT $44.35
  • Revenue Growth
  • TNGX N/A
  • PBT N/A
  • 52 Week Low
  • TNGX $1.03
  • PBT $8.01
  • 52 Week High
  • TNGX $12.02
  • PBT $16.65
  • Technical
  • Relative Strength Index (RSI)
  • TNGX 56.63
  • PBT 67.26
  • Support Level
  • TNGX $6.60
  • PBT $15.64
  • Resistance Level
  • TNGX $7.42
  • PBT $16.50
  • Average True Range (ATR)
  • TNGX 0.47
  • PBT 0.79
  • MACD
  • TNGX -0.04
  • PBT -0.01
  • Stochastic Oscillator
  • TNGX 57.20
  • PBT 92.65

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

About PBT Permian Basin Royalty Trust

Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole and others across Texas. The company earns majority revenue in form of royalties received through its properties.

Share on Social Networks: